Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome : A preliminary study
Copyright © 2018. Published by Elsevier Ltd..
OBJECTIVE: To evaluate the efficacy and safety of secukinumab in Behçet's patients with active mucocutaneous and articular manifestations refractory to previous treatments.
METHODS: We retrospectively evaluated 5 patients treated with the IL17-inhibitor secukinumab and diagnosed with Behçet according to ISG/ICBD criteria. All patients had active mucocutaneous and articular manifestations refractory to colchicine, conventional DMARDs and at least one anti-TNFα agent. Four patients received secukinumab in the dose of 150 mg/monthly since also fulfilling the criteria for ankylosing spondylitis, while the fifth patient received secukinumab 300 mg/monthly because she met psoriatic arthritis criteria. Achievement of response was based on the number of oral ulcers, BASDAI and ASDAS for articular involvement, and BDCAF for Behçet activity. Complete response was defined as: i) decrease ≥50% in the number of oral ulcers; ii) BASDAI index <4; iii) ASDAS index <1.4; iv) decrease of 50% or more in BDCAF index.
RESULTS: The patient starting secukinumab 300 mg/month successfully achieved complete response within 3 months. Complete response was maintained during all 9-months follow-up. Among the 4 subjects starting secukinumab 150 mg/month, two achieved complete response at month 6, but one relapsed. This patient and the two who not achieved complete response at month 6 were switched to secukinumab 300 mg/month. Within 3 months from the dosage increase, all three subjects successfully (re)achieved complete response.
CONCLUSION: Our study suggested for the first time that secukinumab (either 150 mg and 300 mg/month) improved active mucocutaneous manifestations refractory to previous treatments, while secukinumab 300 mg/monthly resulted superior in inducing articular and complete response in Behçet's patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:97 |
|---|---|
| Enthalten in: |
Journal of autoimmunity - 97(2019) vom: 15. Feb., Seite 108-113 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Di Scala, Gerardo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Ankylosing spondylitis |
|---|
| Anmerkungen: |
Date Completed 26.05.2020 Date Revised 26.05.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaut.2018.09.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM288504232 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM288504232 | ||
| 003 | DE-627 | ||
| 005 | 20231225060446.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaut.2018.09.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0961.xml |
| 035 | |a (DE-627)NLM288504232 | ||
| 035 | |a (NLM)30213443 | ||
| 035 | |a (PII)S0896-8411(18)30434-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Di Scala, Gerardo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome |b A preliminary study |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.05.2020 | ||
| 500 | |a Date Revised 26.05.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018. Published by Elsevier Ltd. | ||
| 520 | |a OBJECTIVE: To evaluate the efficacy and safety of secukinumab in Behçet's patients with active mucocutaneous and articular manifestations refractory to previous treatments | ||
| 520 | |a METHODS: We retrospectively evaluated 5 patients treated with the IL17-inhibitor secukinumab and diagnosed with Behçet according to ISG/ICBD criteria. All patients had active mucocutaneous and articular manifestations refractory to colchicine, conventional DMARDs and at least one anti-TNFα agent. Four patients received secukinumab in the dose of 150 mg/monthly since also fulfilling the criteria for ankylosing spondylitis, while the fifth patient received secukinumab 300 mg/monthly because she met psoriatic arthritis criteria. Achievement of response was based on the number of oral ulcers, BASDAI and ASDAS for articular involvement, and BDCAF for Behçet activity. Complete response was defined as: i) decrease ≥50% in the number of oral ulcers; ii) BASDAI index <4; iii) ASDAS index <1.4; iv) decrease of 50% or more in BDCAF index | ||
| 520 | |a RESULTS: The patient starting secukinumab 300 mg/month successfully achieved complete response within 3 months. Complete response was maintained during all 9-months follow-up. Among the 4 subjects starting secukinumab 150 mg/month, two achieved complete response at month 6, but one relapsed. This patient and the two who not achieved complete response at month 6 were switched to secukinumab 300 mg/month. Within 3 months from the dosage increase, all three subjects successfully (re)achieved complete response | ||
| 520 | |a CONCLUSION: Our study suggested for the first time that secukinumab (either 150 mg and 300 mg/month) improved active mucocutaneous manifestations refractory to previous treatments, while secukinumab 300 mg/monthly resulted superior in inducing articular and complete response in Behçet's patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Ankylosing spondylitis | |
| 650 | 4 | |a Behçet's syndrome | |
| 650 | 4 | |a Interleukin-17 | |
| 650 | 4 | |a Oral aphthosis | |
| 650 | 4 | |a Psoriatic arthritis | |
| 650 | 4 | |a Secukinumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Interleukin-17 |2 NLM | |
| 650 | 7 | |a secukinumab |2 NLM | |
| 650 | 7 | |a DLG4EML025 |2 NLM | |
| 700 | 1 | |a Bettiol, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Cojan, Rafaela Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Finocchi, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Silvestri, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Emmi, Giacomo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of autoimmunity |d 1989 |g 97(2019) vom: 15. Feb., Seite 108-113 |w (DE-627)NLM012637491 |x 1095-9157 |7 nnns |
| 773 | 1 | 8 | |g volume:97 |g year:2019 |g day:15 |g month:02 |g pages:108-113 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaut.2018.09.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 97 |j 2019 |b 15 |c 02 |h 108-113 | ||